Healthcare · NSE: DIVISLAB
Intrynsic's multi-model valuation estimates Divi's Laboratories Limited's fair value at ₹2,980 per share (range ₹1,065–₹3,298) against a market price of ₹9,431 - a gap of -68.4% (updated 29 September 2026). This is an estimated fair value based on stated assumptions, not investment advice.
Market price
₹9,431
close of 29 Sept 2026
Est. fair value
₹2,980
₹1,065–₹3,298
Gap
-68.4%
price vs estimate
Trading ~68% above our estimated fair-value range. Assumptions and per-model workings are below.
Divi's Laboratories makes active pharmaceutical ingredients and custom-synthesis products for global drug companies. Its earnings depend on manufacturing efficiency and long-term supply contracts with large pharma clients.
Healthcare · Healthcare Services
Over the last 3 years, revenue grew 10.8%/yr and profit grew 12.1%/yr.
Every ₹100 of shareholder money earned ₹15.3 in profit last year, vs a sector median of 10.6%.
It holds more cash than debt.
The market price is above our estimated fair-value range (based on stated assumptions).
About ₹16 of every ₹100 of reported profit turned into free cash (median, last 5 years); operating cash flow was positive in 5 of 5 years.
Intrynsic values Divi's Laboratories Limited with 3 independent models and blends them into one estimated fair-value range. Every number below is an estimate based on the stated assumptions - change the assumptions and the estimate changes.
| Model | Estimated value | vs price | Weight |
|---|---|---|---|
| DCFFuture Cash Flows Method | ₹1,065 | -89% | - |
| EV/EBITDAIndustry Comparison Method | ₹2,980 | -68% | - |
| P/E MultipleEarnings Multiple Method | ₹3,298 | -65% | - |
Reverse DCF: today's market price implies the company must grow free cash flow about 60.0% a year for the next decade - versus 4.2% historical revenue growth.
| Revenue | ₹10,560 Cr | |
| Net profit | ₹2,568 Cr | |
| EPS | ₹96.73 | |
| Free cash flow | ₹218 Cr | |
| ROE (latest) | 15.3% | |
| Revenue growth (CAGR) | 11.2% | |
| Profit growth (CAGR) | 10.3% |
Intrynsic's multi-model valuation estimates Divi's Laboratories Limited's fair value at ₹2,980 per share (range ₹1,065–₹3,298), last updated 29 September 2026. This is an estimate based on stated assumptions, not investment advice.
Divi's Laboratories Limited trades at ₹9,431 against Intrynsic's estimated fair value of ₹2,980 - the market price is 68% above the estimate, i.e. above our estimated fair-value range. Different assumptions produce different estimates; see the model breakdown above.
Divi's Laboratories Limited trades at about 97.5 times its latest annual earnings per share.
Divi's Laboratories makes active pharmaceutical ingredients and custom-synthesis products for global drug companies. Its earnings depend on manufacturing efficiency and long-term supply contracts with large pharma clients.
Intrynsic runs 3 valuation models for Divi's Laboratories Limited (DCF, EV/EBITDA, P/E Multiple) and blends them into one estimated fair-value range. Every assumption - growth, discount rate, terminal value - is shown openly on this page.
Disclaimer: Intrynsic provides educational and informational analysis only. Fair-value figures are estimates based on stated assumptions - they are not investment advice, research recommendations, or an offer to transact in any security. Intrynsic is not a SEBI-registered investment adviser or research analyst. Markets carry risk; please do your own research or consult a registered adviser before making investment decisions. Prices shown may be delayed end-of-day values. Terms · Privacy